"The administration has legitimate reasons to guard against investments that could strengthen China's military capabilities...But ordinary pharmaceutical research should not be treated as a national security threat merely because it originates in China."
forbes.com/sites/sallypipes/…
10
"The newly proposed rule from the Treasury Department would heavily restrict or outright prohibit American individuals and companies from partnering with and investing in Chinese biotechnology companies."
More on COINS: thewellnews.com/opinions/new…
7
COINS is "meant to enhance our national security by preventing American resources from building up China’s already growing biotech capabilities...the proposal is so broad that it could hurt American biotech companies far more than it hurts Chinese ones."
fortune.com/2026/11/12/roy-b…
14
"What could proposed restrictions on U.S. investment in Chinese biotechnology mean for the 194 million Americans living with chronic conditions?"
More on the impact of the COINS Act:
youtube.com/watch?v=K1yt-LcM…
28
"The U.S. Department of the Treasury released a notice of proposed rulemaking to implement the COINS Act, which establishes a framework for evaluating and restricting certain U.S. investments involving countries of concern, including China."
americanactionforum.org/insi…
11
"Studies have shown that countries with stronger #IP systems tend to be more innovative, while weaker IP systems may stifle innovation.
In essence, a strong innovation economy requires a strong IP system."
fortune.com/2026/10/20/forme…
11
"Reliable #IP protections reduce investment risk in an industry defined by long timelines and high failure rates, while allowing specialized companies to focus on speeding up the broader drug development pipeline."
thedailyrecord.com/2026/10/2…
14
"This calculus makes disabled people less worthy of treatment — not because our lives are shorter, but because the system sees us as less valuable."
More on the impact of #QALYs: dailywire.com/news/i-had-a-r…
24
"Prior authorization makes money for insurers. Every delay and every denial can mean care that never gets paid for.
Companies don’t easily give up tools that pad their bottom line."
healthcareuncovered.substack…
1
1
26
"Can America strengthen its biotech leadership by restricting China—or should it focus on making the United States the best place in the world to develop new medicines?"
Tune in to learn more: youtube.com/watch?v=ijDqz8Md…
13
"We need to remove the barriers patients face when trying to access their medicines, not institute pricing policies like MFN that are proven to make these problems worse. We should fix insurance and protect the innovation we depend on to save lives."
nopatientleftbehind.org/medi…
14
"The United States accounts for about 75% of global pharmaceutical profits, despite representing roughly 5% of the world’s population...That imbalance matters because new medicines benefit patients worldwide."
truthonthemarket.com/2026/10…
11
"This foreign free-riding doesn’t just lead to higher prices in the United States. Over time, it can also mean fewer new medicines for patients everywhere."
#MFN impacts are widespread: washingtonexaminer.com/op-ed…
15
"Price controls in Europe have coincided with a gradual contraction of the continent’s biotech sector and more limited patient access to new medicines. Policymakers must approach any similar policy shift here clear-eyed about the potential trade-offs."
nationalreview.com/2026/10/a…
20
American #IP protections ensure the U.S. leads in life sciences.
A new @weworkforhealth blog details how #IPRights help America turn ideas into breakthroughs: weworkforhealth.org/post/250…
10
#MFN "would not fix coverage denials, insurance delays, or high out-of-pocket costs. Nor would it guarantee that lower prices reach patients at the pharmacy counter."
realclearhealth.com/articles…
10
"If China becomes the global biotech leader, it will give Beijing significant leverage over America’s health and security in future crises. It’ll also weaken America’s ability to shape the future of medicine, profoundly damaging our economy."
statnews.com/2026/09/30/chin…
12
"Insurers rigged the system, counting billions in overhead, marketing and other costs as ‘medical’ expenses. We need real transparency to make sure health dollars go to patients — not just insurers’ bottom line."
dailycaller.com/2026/09/17/i…
10
"The lesson from the #IRA and other countries around the world is simple: Government drug price controls do not improve patient access. In many cases, price controls create incentives to ration care and empower government bureaucrats."
thehill.com/opinion/healthca…
18
"Drawing on nearly three decades of AUTM licensing survey data, the report finds that Bayh-Dole-enabled technology transfer has helped launch more than 19,000 startups and 17,000 new products."
More in the newly released report: bayhdolecoalition.org/wp-con…
12
